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Abstract
3-O-3′(or 2′)-methylsuccinyl-betulinic acid (MSB) derivatives were separated by using recycle
HPLC. The structures of four isomers were assigned by NMR and asymmetric synthesis. 3-O-3′S-
Methylsuccinyl-betulinic acid (3′S-MSB, 4) exhibited potent anti-HIV activity with an EC50 value
of 0.0087 μM and a TI value of 6.3×103, which is comparable to the data for bevirimat (DSB,
PA-457), a current clinical trials drug that was also derived from betulinic acid. The anti-HIV potency
of 4 was slightly better than that of AZT.
Highly active antiretroviral therapy (HAART) combines several anti-HIV drugs with different
targets, and its use has significantly improved AIDS treatment.1-3 However, it has also led to
some serious problems, such as increased toxicities and emergence of multi-drug resistant HIV
viral strains.4-7 Therefore, new classes of compounds with novel modes of action against HIV
are still urgently needed.
We initially identified betulinic acid (BA, 1) as an anti-HIV lead compound with an EC50 1.4
μM and therapeutic index (TI) 9.3 from the leaves of Syzygium claviflorum.8 Our subsequent
modification study resulted in the discovery of 3-O-(3′,3′-dimethylsuccinyl)-betulinic acid
(bevirimat, DSB, PA-457, 2). Bevirimat exhibits extremely potent anti-HIV activity with an
EC50 value of <0.00035 μM and a TI value of >20,000.9,10 It was found to inhibit HIV-1
replication by interfering with a previously unidentified viral target, HIV-1 P24/P25
processing, resulting in the production of a noninfectious HIV-1 particle.11,12 Therefore,
bevirimat represents a unique first in a class of anti-HIV compounds termed maturation
inhibitors (MIs). Bevirimat has recently succeeded in Phase IIa clinical trials and is currently
in Phase IIb clinical trials.13,14
Our prior structure-activity relationship (SAR) study of 2 and other 3-O-acyl-betulinic acid
derivatives suggested that the proper length, a terminal carboxylic acid, and C-3′ dimethyl
substitution of the C-3 side chain contribute to enhanced anti-HIV activity.9,15 However, it is
still unclear which, if either, C-3′ methyl group within the C-3 side chain of 2 contributes more
toward activity. Therefore, 3-O-monomethylsuccinyl betulinic acid (MSB) derivatives were
designed to investigate the impact of these methyl groups. This paper reports their synthesis,
isolation, structural assignment, and SAR study.
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Betulinic acid was treated with 2-methylsuccinic anhydride and DMAP in pyridine at reflux
to furnish the 3′-MSB racemic isomers, as well as the undesired 2′-MSB isomers. The
separation of the four compounds (3-6)16 was challenging, since they differ only by the
presence of a 2′ or 3′ (R or S) methyl group, but was successfully achieved by using recycle
preparative HPLC (Figure 1).17 The purities of 3-6 were ascertained by analytical HPLC
(Figure 2). By comparing the 1H-NMR spectra of the purified isomers with those of 2 and 3-
O-2′,2′-dimethylsuccinyl BA, peaks 1 and 2 were assigned as the 3′-MSBs, and peaks 3 and 4
as the 2’-MSBs. However, we still needed to determine the stereochemistry of the C-3′ and
C-2′ chiral centers. Therefore, the 3′R and 3′S isomers were also prepared through asymmetric
synthesis as described below.
As shown in Scheme 1, the hydroxy group of 3R-bromo-2-methylpropanol was first protected
by reaction with TBDPSCl in DMF. The bromide group was then replaced with an aldehyde
group by reaction first with sodium cyanide in DMSO, followed by reduction using DIBALH.
18 The aldehyde was oxidized to a carboxylic acid in the presence of NaClO2 and NaH2PO4
in DMSO to yield 9a. Reaction of 1 with 9a in the presence of EDCI and DMAP led to
esterification of the 3β-hydroxy group of 1 with the carboxylic acid of 9a to provide 10a. After
cleavage of the TBDPS group with TBAF in THF, the primary hydroxy group of 11 was
oxidized to a carboxylic acid in the presence of TEMPO, PhI(OAc)2 in a solution of H2O-
CH2Cl2 to give 3-O-(3′R-methylsuccinyl)-betulinic acid (3′R-MSB, 3). The 3′S-MSB isomer
(4) was synthesized using the same method starting with 3S-bromo-2-methylpropanol. By
comparing the HPLC retention times and 1H-NMR spectra of these compounds, we determined
that peak 1 is the 3′S diastereoisomer and peak 2 is the 3′R diastereoisomer.
Furthermore, the reaction of 2R-methylsuccinic anhydride with betulinic acid yielded the 3′R-
MSB (3) and 2′R-MSB (5) isomers. The HPLC retention time indicated that peak 4 is the 2′R
isomer (5). Similarly, peak 3 was confirmed as the 2′S isomer (6). Thus, the stereochemistry
of the 3′ or 2′ chiral center in 3–6 was fully determined.
Anti-HIV activities of all four synthetic compounds (3–6) and 2 were evaluated according to
the procedure described in Refs 19 and 20. The synthetic intermediate 12 and a 1:1 mixture
(13) of the 3′R- and 3′S-MSB isomers (3 and 4) were also tested.
The anti-HIV activities of the synthesized compounds are summarized in Table 1. Among these
derivatives, the 3′S-MSB isomer (4) showed very potent anti-HIV activity with a TI of
6.3×103 and EC50 of 0.0087 μM, which is comparable to that of 2 (EC50: 0.0013 μM) and
slightly better than that of AZT (EC50: 0.034 μM) in this assay system. The 3′R-MSB isomer
(3) exhibited only moderate anti-HIV activity with a TI of 9.6×102 and EC50 of 0.12 μM. The
antiviral activity (EC50: 0.016 μM) of the mixture (13) of the two stereoisomers falls in between
those of 3 and 4. This result indicates that the two C-3′methyl groups in the DSB side chain
contribute differently to the extremely potent anti-HIV activity of this compound class. We
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postulate that an interaction of the 3′S-methyl group with the viral target might be essential to
the anti-HIV activity of 2. The interaction of the 3′R-methyl group within the target is less
significant, but still necessary, since 2, with dimethyl substitution at C-3′, is slightly more
potent than the 3′S-MSB isomer (4). In comparison with 3 and 4, both 2′-MSBs (5, 6) exhibited
no or little activity in the same assay. These results agree with our previous SAR study,
indicating that methyl substitution at the C-3′ position improves the antiviral activity much
more significantly than at the C-2′ position.
In addition, compound 12, which differs structurally from 3 only in the replacement of a
primary hydroxyl group for a terminal carboxylic acid in the 3-O-acyl side chain, had no
activity. This result is also consistent with our findings in prior studies that the terminal
carboxylic acid is essential for enhanced antiviral activity.15
In conclusion, 3′ MSBs and 2′MSBs were prepared in our study to investigate the SAR of the
C-3′ chiral center of the anti-HIV clinical trials agent bevirimat (2). Our results suggest that
the 3′S-methyl group of 2 is the major contributor to the compound’s extremely high anti-HIV
potency, since 2 and 3′S-MSB (4) exhibit comparable anti-HIV activity, while the 3′R isomer
shows much lower activity.
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JAI LC-918 Recycling Preparative HPLC. Mobile phase: 85% ACN 0.1% TFA; flowrate: 5.0
mL/min; Detector: Refractive Index (RI); Column: Alltima C18 5μ 250 mm × 22 mm. Peak
1: 3-O-(3′S-methylsuccinyl)betulinic acid (4); Peak 2: 3-O-(3′R-methylsuccinyl)-betulinic
acid (3); Peak 3: 3-O-(2′S-methylsuccinyl)-betulinic acid (6); Peak 4: 3-O-(2′R-
methylsuccinyl)-betulinic acid (5)
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Purity confirmation of the four MSB (3-6) isomers by Shimadzu LC-20AT. Column: Alltima
C18 5μ 150 mm × 2.1 mm.
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Reagents and conditions: a) TBDPSCl, imidazole, quant; b) NaCN, DMSO, 93%; c) DIBALH,
95%; d) NaClO2, NaH2PO4, DMSO, quant; e) EDCI, DMAP, BA, 25-48%; f) TBAF, THF,
quant; g) TEMPO, PhI(OAc)2, H2O, CH2Cl2, 75-88%
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AZT 0.034 1,870 55,330
2 0.0013 > 42.78 30,555
3 0.12 > 43.83 961
4 0.0087 32.78 6,274
5 No Suppression > 43.83 –
6 0.44 > 43.83 100
12 No Suppression > 44.93 –
13 0.016 > 44.93 5,323
a
: concentration that inhibits HIV-1 replication by 50%
b
: concentration that is toxic to 50% of mock-infected MT-2 cells
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